Eptinezumab

Eptinezumab (formerly ALD403[1]) is an experimental drug being developed by Alder Biopharmaceuticals for the treatment of migraine. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.[2][3] It is in Phase III clinical trials as of August 2017.[4]

Eptinezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCALCA, CALCB
Clinical data
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6352H9838N1694O1992S46
Molar mass143283.20 g·mol−1

See also

References
  1. http://investor.alderbio.com/releasedetail.cfm?releaseid=1001091
  2. Dodick, David W; Goadsby, Peter J; Silberstein, Stephen D; Lipton, Richard B; Olesen, Jes; Ashina, Messoud; Wilks, Kerri; Kudrow, David; Kroll, Robin; Kohrman, Bruce; Bargar, Robert; Hirman, Joe; Smith, Jeff (2014). "Safety and efficacy of eptinizumab, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet Neurology. 13 (11): 1100. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013.
  3. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 31 (1). 2017.
  4. "Pipeline". Alder Biopharmaceuticals.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.